Now that we know they have this defense mechanism, we might be able to precisely disable it
In the quiet corridors of a Montana laboratory, mice that should not have survived revealed that life holds more ingenuity than science had credited it with. Researchers at Montana State University have spent nearly a decade confirming what a 2014 anomaly first suggested: cells possess a hidden backup system for producing cysteine, an amino acid long considered irreplaceable through known pathways alone. The discovery, published in Nature Chemical Biology in 2026, does not merely revise a chapter of cellular biology — it illuminates a possible reason why cancer so stubbornly resists the treatments we aim at it, and points toward a new way of disarming it.
- Mice engineered to lack all known cysteine-producing machinery survived anyway, defying a biological rule that had stood unchallenged for decades.
- Nine years of investigation across multiple institutions gradually mapped a shadow pathway — cells cleaving a different chemical bond in cystine to liberate the cysteine they need.
- The ancient defense mechanism that once shielded early organisms from environmental toxins may now be the very shield cancer cells raise against chemotherapy, radiation, and immunotherapy.
- Scientists now hold a potential strategic key: precisely disabling this backup system in tumor cells could strip away a layer of their resistance and make existing treatments dramatically more effective.
- The work, co-authored in part by undergraduate students, stands as a reminder that a single unexplained observation — pursued with patience — can quietly overturn an entire field.
In 2014, Ed Schmidt watched mice survive something that biology said was impossible. He had removed the cellular machinery these animals were supposed to need to produce cysteine — an amino acid essential for building proteins and protecting cells from damage. By every established rule, they should have died. They did not.
Schmidt, a molecular geneticist at Montana State University, spent the next seven years proving what that anomaly implied: cells carry a backup system for cysteine production that no one had previously discovered. When the two primary pathways fail, the cell finds another route — chemically severing a different bond in cystine, the oxidized precursor molecule, and releasing usable cysteine all the same. Working with collaborator Peter Nagy at the Hungarian National Institute of Oncology in Budapest, Schmidt's team mapped this hidden mechanism in full. Their findings appeared in Nature Chemical Biology in May 2026.
The discovery rewrites a foundational assumption of cellular biology, but its most urgent implications point toward cancer. This backup system likely evolved millions of years ago to protect early organisms from electrophilic toxins — poisons produced by plants and microbes in their environment. That same ancient defense, Schmidt realized, may be precisely what allows tumor cells to endure chemotherapy, radiation, and immunotherapy. Cancer has learned to exploit a survival trick as old as multicellular life itself.
The strategic opening is now visible: if researchers can find a way to disable this mechanism selectively in cancer cells, they may be able to strip away one of the tumor's most durable shields, making existing treatments far more lethal to it. Several of Schmidt's undergraduate students served as co-authors on the work — a detail that speaks to the culture of the laboratory and to the long, patient nature of the inquiry. A single observation of something that should not have happened, held onto and pursued with rigor across nearly a decade, has identified a new vulnerability at the heart of how cancer protects itself.
In 2014, Ed Schmidt watched something happen that shouldn't have been possible. Mice in his laboratory at Montana State University survived without the cellular machinery that every living thing was supposed to need to stay alive. They had no way to make cysteine, an amino acid essential for building proteins and defending cells against damage. By the rules of biology as scientists understood them, these mice should have died.
Schmidt is a molecular geneticist in the Department of Microbiology and Cell Biology. He had engineered the mice deliberately, removing one or both of the two primary systems cells use to convert cystine—an oxidized form of cysteine—into the cysteine they need to survive. For decades, researchers had accepted as fundamental law that this conversion process, called a disulfide reductase system, was non-negotiable. No organism had ever been found that could live without it. Yet here were living, breathing mice that had somehow broken that rule.
What Schmidt suspected, and what he spent the next seven years proving, was that cells possessed a backup system nobody had discovered. When the primary pathways failed, something else kicked in. Working with Peter Nagy, a collaborator at the Hungarian National Institute of Oncology in Budapest, Schmidt's team eventually mapped how this hidden mechanism worked. When cells couldn't access their normal routes to cysteine, they chemically severed a different bond in the cystine molecule—a carbon-sulfur connection adjacent to the one the primary system would normally break. The result was the same: cysteine released and available for the cell to use.
The findings, published in May 2026 in Nature Chemical Biology, rewrite what scientists thought they knew about cellular survival. But the implications extend far beyond basic biology. This backup system likely evolved millions of years ago as a defense mechanism. Cells needed protection from electrophilic toxins—organic molecules produced by organisms in their environment or in their food sources, designed to kill anything that would eat them. The ability to survive without the primary cysteine-making systems, at least temporarily, gave early multicellular organisms a way to resist these poisons.
That same protective mechanism, Schmidt realized, might be exactly what allows cancer cells to survive chemotherapy, radiation, and immunotherapy. Tumors have learned to exploit this ancient backup system, using it as a shield against treatments designed to kill them. The discovery opens a new strategic possibility: if researchers can identify how to precisely disable this defense in cancer cells, they might strip away one layer of the tumor's protection, making existing therapies far more effective.
"Now that we know they have this defense mechanism, we might be able to precisely disable it in cancers, making them more susceptible to cancer therapies," Schmidt said in a statement about the work.
The research spanned nine years and involved multiple institutions. Several of Schmidt's undergraduate students—Zoe Seaford and Sydney Austad as co-first authors, along with Martina Serrano Alvarez and Reed Noyd—did their work in his laboratory while still completing their degrees. Colin Miller, a doctoral student, also contributed. The collaborative effort underscores how a single observation of something that shouldn't happen can, when pursued with rigor and patience, reshape an entire field.
Schmidt joined Montana State in 1999 and has built a research program around understanding gene regulation, cellular physiology, and the genetics of laboratory mice. This discovery may prove to be his most consequential work—not because it solves cancer, but because it identifies a new vulnerability in how cancer cells protect themselves. The next phase will be translating that knowledge into drugs or therapies that can exploit it.
Citações Notáveis
This was supposed to be impossible. No living organism or cell had ever been found that could live without having a functioning disulfide reductase system.— Ed Schmidt, molecular geneticist at Montana State University
Now that we know they have this defense mechanism, we might be able to precisely disable it in cancers, making them more susceptible to cancer therapies.— Ed Schmidt
A Conversa do Hearth Outra perspectiva sobre a história
When you say the mice shouldn't have survived, what exactly would have happened to a normal mouse in that situation?
Without any way to make cysteine, the cells would have starved. Cysteine isn't something you can get from food or from outside the cell—cells have to manufacture it themselves. No cysteine means no proteins, no defense against damage. The organism dies.
So for seven years you were essentially asking: how are these mice alive?
Exactly. We knew something was happening that contradicted what we thought was settled science. The mice were making cysteine somehow. We just had to figure out the mechanism.
And when you found it—this backup system that severs a different bond—did that feel like discovering a loophole in nature?
More like discovering we'd been looking at the wrong door. The system was always there. We just couldn't see it because we were so certain the primary system was the only way.
Does this change how you think about cancer cells?
It reframes them as more resourceful than we gave them credit for. They're not just dividing uncontrollably—they're actively using ancient survival mechanisms we didn't even know existed. That's both humbling and, potentially, useful.
Useful how?
If cancer cells are dependent on this backup system to survive our treatments, then disabling it becomes a target. You're not trying to kill the cancer directly—you're removing its escape route.